3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
10
Brain Neoplasms
3
Leukemia, Hairy Cell
2
Uveal Melanoma
1
Thyroid Neoplasms
1
Solid Tumors
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Carcinoma
1
Neoplasm Metastasis
1
Glioma
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Craniopharyngioma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
23
Cisplatin
22
durvalumab
13
pembrolizumab
8
Oxaliplatin
7
Capecitabine
7
Fluorouracil
6
Leucovorin
5
Bevacizumab
5
lenvatinib
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
Nivolumab
3
Liquid Biopsy
3
Injections
3
Folfox protocol
3
zanidatamab
2
trifluridine tipiracil drug combination
2
tremelimumab
2
tislelizumab
2
ivosidenib
2
futibatinib
2
apatinib
2
Trastuzumab
2
Taxes
2
Irinotecan
2
Immune Checkpoint Inhibitors
2
Drug Therapy
2
Carboplatin
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Biliary Tract Neoplasms
×
binimetinib
×
Clear all
NCT05615818
2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3
Recruiting
800 enrolled